Overview
1.3 ATA is the pressure delivered by most soft-shell portable chambers used for home or wellness HBOT. At this depth a patient breathes 85–95% oxygen and the increased pressure dissolves additional oxygen into plasma — though substantially less than clinical-grade 2.0–2.4 ATA protocols. The FDA has cleared 1.3 ATA chambers only for acute mountain sickness; use for other indications is off-label and clinical efficacy remains debated.
1.3 ATA mild HBOT occupies a controversial position in the hyperbaric landscape. The pressure is low enough to be delivered safely in soft-shell portable chambers with minimal engineering requirements, enabling home use at consumer price points ($5,000–$20,000). This accessibility has driven a large wellness and off-label market that has grown substantially over the past two decades.
Pharmacologically, 1.3 ATA produces significantly less dissolved plasma oxygen than clinical HBOT at 2.0 ATA or above. Arterial oxygen tension at 1.3 ATA with 95% oxygen is roughly 3× normal atmospheric breathing — meaningful but modest compared to the 10× increase at 2.0 ATA with 100% oxygen. Whether this is enough to produce clinically meaningful effects for most off-label indications remains contested within the hyperbaric medical community.
The regulatory position is clear: FDA-cleared only for acute mountain sickness. All other use — TBI, long COVID, autism, anti-ageing, sports recovery, general wellness — is off-label from a device-clearance perspective, regardless of what marketing materials claim.
How It Works
The chamber is pressurised to approximately 1.3 ATA (about 4.4 psi above atmospheric) using an electric air blower. A separate oxygen concentrator feeds 85–95% oxygen either into the chamber environment or via a mask inside. The patient (or user, in home settings) remains inside the sealed fabric chamber for 60–90 minutes. Compression and decompression are slow (10–15 minutes each). The resulting elevation in dissolved plasma oxygen is modest compared to clinical HBOT but produces measurable physiological changes.
Protocol Parameters
| Pressure | 1.3 ATA (≈ 4.4 psi above atmospheric) |
|---|---|
| Session length | 60–90 minutes |
| Frequency | 3–5 sessions/week |
| Typical course | 20–40 sessions |
Indications
- Altitude sickness (FDA-cleared)
- General wellness / recovery (off-label)
- Experimental neurological protocols
FDA-cleared only for acute mountain sickness. Off-label use includes TBI, concussion recovery, long COVID, autism, anti-ageing, sports recovery, and general wellness. The evidence base for off-label indications at 1.3 ATA is substantially weaker than the clinical evidence at 2.0+ ATA.
Evidence Base
Limited RCT data at this pressure. Most positive studies cited for soft-shell HBOT fall below the UHMS threshold for recognised medical indications. Rossignol 2009 autism RCT and Harch veteran trials are the most-cited positive 1.3–1.5 ATA studies; both have had inconsistent replication.
The strongest HBOT evidence for neurological indications uses 2.0 ATA (Efrati Lab TBI, stroke, long COVID). 1.3 ATA has produced some positive signals (Rossignol 2009 in autism) but larger follow-up trials have been mixed. The pressure-dependent nature of HBOT efficacy is a central question in the ongoing debate about mild HBOT.
Cautions & Notes
- Not sufficient for UHMS-approved emergency indications (DCS, CO poisoning)
- Clinical efficacy for TBI/stroke at 1.3 ATA remains inconsistent across trials
- FDA clearance limited to altitude sickness; all other use is off-label
- Marketing claims frequently exceed the published evidence
- Soft-shell chamber safety requires strict fire protocols (cotton clothing, no electronics)
Practical Considerations
For users with access to clinical 2.0+ ATA HBOT, that is the stronger-evidence option. For users without that access (geography, cost, insurance), 1.3 ATA soft-shell is a reasonable low-risk, lower-benefit alternative with the caveat that evidence is weaker. Home 1.3 ATA chambers are capital-expensive upfront but amortise favourably over long courses.
Frequently Asked Questions
Does 1.3 ATA work for TBI or long COVID?
The strongest HBOT evidence for TBI and long COVID uses 2.0 ATA, not 1.3 ATA. Some positive signals exist at lower pressures but with inconsistent replication. Pressure appears to matter for neurological HBOT efficacy.
Can I use a 1.3 ATA chamber for altitude sickness?
Yes — this is the FDA-cleared indication. Portable soft-shell chambers at 1.3 ATA are used by expedition medicine and in mountain rescue for acute mountain sickness.
Is 1.3 ATA safer than 2.0 ATA?
Technically yes — lower barotrauma risk and lower oxygen toxicity risk. However, both pressures have excellent safety profiles with proper screening and operation. The practical safety difference is minor.
Research disclaimer: This protocol summary is for educational purposes only. HBOT is a regulated medical treatment that must be administered under appropriate professional supervision. Always consult a qualified physician before initiating hyperbaric therapy.